Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype Jan-Hendrik BeumerTessa BuckleOlaf van Tellingen OriginalPaper 05 April 2006 Pages: 1 - 7
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug Esther F. A. BrandonRolf W. SparidansJan H. M. Schellens OriginalPaper 05 April 2006 Pages: 9 - 19
Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line Marta MongeMarta VilasecaRicardo Pérez-Tomás OriginalPaper 05 April 2006 Pages: 21 - 29
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines Yasuhiko KanoMiyuki AkutsuYusuke Furukawa Preclinical Studies 22 July 2006 Pages: 31 - 40
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer Jehana JamesDaryl J. MurryKathy D. Miller PHASE I STUDIES 13 September 2006 Pages: 41 - 48
Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study Dahua ZhangThomas PierAndreas Friedl Phase I Studies 26 September 2006 Pages: 49 - 55
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study Hector Soto ParraRaffaele CavinaArmando Santoro OriginalPaper 11 May 2006 Pages: 57 - 62
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer Neelima DenduluriJames J. LeeSandra M. Swain Phase II Studies 25 August 2006 Pages: 63 - 67
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma Ulka N. VaishampayanLance K. HeilbrunLawrence E. Flaherty Phase II Studies 26 August 2006 Pages: 69 - 75
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial Chia-Chi LinChiun HsuChih-Hsin Yang Phase II Studies 26 August 2006 Pages: 77 - 84
Phase II trial of nolatrexed dihydrochloride [ThymitaqTM, AG 337] in patients with advanced hepatocellular carcinoma Minaxi JhawerLee RosenSridhar Mani Phase II Studies 07 September 2006 Pages: 85 - 94